850101P

13:0 Lyso PI

1-tridecanoyl-2-hydroxy-sn-glycero-3-phospho-(1′-myo-inositol) (ammonium salt), powder

• 同義詞: PI(13:0/0:0); 110716
• 經驗公式（希爾表示法）: C₂₂H₄₆NO₁₂P
• CAS號碼: 1246430-02-3
• 分子量：: 547.57
• 分類程式碼代碼: 51191904
• NACRES: NA.25

屬性

• 化驗: >99% (LPI; may contain up to 10% of the 2-LPI isomer, TLC)
• 形狀: powder
• 包裝: pkg of 1 × 100 μg (with stopper and crimp cap (850101P-100ug)); pkg of 1 × 500 μg (with stopper and crimp cap (850101P-500ug))
• 製造商／商標名: Avanti Research^™ - A Croda Brand 850101P
• 脂質類型: phospholipids; cardiolipins
• 運輸包裝: dry ice
• 儲存溫度: −20°C
• SMILES 字串: [H][C@@](COP([O-])(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O)=O)(O)COC(CCCCCCCCCCCC)=O.[NH4+]

描述

一般說明

Lysophosphatidylinositol (LPI), produced by phospholipase A2 is a bioactive lipid.

應用

13:0 Lyso PI (1-tridecanoyl-2-hydroxy-sn-glycero-3-phospho-(1′-myo-inositol) may be used as a nonendogenous phospholipid (PL) standard for the quantitative analysis of PLs. It may also be used as a standard for tandem mass spectrometry analysis of lipid species in human plasma.

生化／生理作用

Increased circulating levels of L-alpha-lysophosphatidylinositol (LPI) are associated with cancer and LPI is a potent ligand for the G-protein-coupled receptor GPR55.

Lysophosphatidylinositol (LPI) is expected to play a vital role in various diseases. Ca²⁺ channels at the plasma membrane and mitochondrial membrane are controlled by LPI. It can also stimulate various signaling pathways to control several cellular processes. LPI can block the migration of cells.

包裝

2 mL Amber Serum Vial with Stopper and Crimp Cap (850101P-100ug)

2 mL Amber Serum Vial with Stopper and Crimp Cap (850101P-500ug)

法律資訊

Avanti Research is a trademark of Avanti Polar Lipids, LLC

安全資訊

• 儲存類別代碼: 11 - Combustible Solids